Enter your keyword

Developing Innovative Therapeutic Approaches To Treat Cancer

Other Programs

Concurrent with the clinical development of OXi4503, the following other programs are underway:

  • Investigating the potential use of CA4P in immuno-oncology in combination with checkpoint inhibitors in preclinical models. This work is being conducted in collaboration with researchers at the University of Florida and the University of Arhus.
  • Gastrointestinal and pancreatic neuroendocrine tumors (GI-NETs and PNETs) are highly vascularized tumors that cause a cascade of disease symptoms, resulting in significant morbidity for the patient. Preclinical data have evaluated the efficacy of systemic administration of CA4P for the treatment of functional insulinomas in a transgenic mouse model of PNETs. In the model, treatment with CA4P resulted in a significant and sustained decrease in circulating insulin, with maximum effect seen by day 17 (P<0.0001). Treatment with CA4P disrupted tumor vasculature, induced apoptosis and inhibited tumor cell proliferation, and appeared to be well tolerated, with no obvious toxicity.